Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15285632 | 0.98 | HCRTR2 (0.42) | EPHX1HCRTR2TDP1MAOAMAOB | |
| SCHEMBL29713169 | 0.95 | HCRTR2 (0.42) | EPHX1HCRTR2TDP1MAOAMAOB | |
| SCHEMBL2943075 | 0.91 | HCRTR2 (0.43) | EPHX1HCRTR2TDP1MAOAMAOB | |
| SCHEMBL16846897 | 0.84 | HCRTR2 (0.45) | EPHX1HCRTR2TDP1MAOAMAOB | |
| SCHEMBL25785532 | 0.81 | HCRTR2 (0.45) | EPHX1HCRTR2TDP1MAOAMAOB | |
| SCHEMBL89465 | 0.81 | EPHX1 (0.44) | EPHX1HCRTR2TDP1MAOAMAOB | |
| SCHEMBL27995921 | 0.81 | EPHX1 (0.41) | EPHX1HCRTR2TDP1MAOAMAOB | |
| SCHEMBL20980330 | 0.80 | HCRTR2 (0.40) | EPHX1HCRTR2TDP1MAOAMAOB | |
| SCHEMBL24230207 | 0.80 | EPHX1 (0.43) | EPHX1HCRTR2TDP1MAOAMAOB | |
| SCHEMBL14690510 | 0.80 | HCRTR2 (0.44) | EPHX1HCRTR2TDP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478295-B1 | SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES | PHARMACOSMOS HOLDING AS (DK) | 2026-05-27 | — | — | EP | disclosed |
| EP-4626423-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20140274896-A1 | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140274896-A1 | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275066-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275066-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271466-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-0772590-B1 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-10-09 | — | — | EP | disclosed |
| US-5714485-A | Piperidine and hexahydropyridazine thrombin inhibitors | MERCK & CO., INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5510369-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1996-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | EPHX1 2749/4885HCRTR2 3029/4885TDP1 2065/4885 |
| US-20140274896-A1 | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation | MCL1, POT1, CTSA | EPHX1 1547/4885HCRTR2 3735/4885TDP1 1694/4885 |
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | CDK6, CCNC, MCL1 | EPHX1 2792/4885HCRTR2 4106/4885TDP1 671/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | EPHX1 2792/4885HCRTR2 4106/4885TDP1 671/4885 |
| US-20140271466-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | RB1, CDK4, CDKN1A | EPHX1 2749/4885HCRTR2 3029/4885TDP1 2065/4885 |
| US-20140275066-A1 | Transient Protection of Normal Cells During Chemotherapy | CDK6, CCNC, MCL1 | EPHX1 2792/4885HCRTR2 4106/4885TDP1 671/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | EPHX1 3515/4885HCRTR2 3650/4885TDP1 563/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | EPHX1 2792/4885HCRTR2 4106/4885TDP1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.